logo
Weekly influenza cases nearly double in Maine over last 3 weeks

Weekly influenza cases nearly double in Maine over last 3 weeks

Yahoo20-02-2025

Feb. 19—Influenza continues to spread rapidly in Maine, with more than 2,000 confirmed cases last week, the Maine Center for Disease Control and Prevention said.
Maine recorded 2,028 cases of influenza for the week ending Feb. 15, the highest so far in the 2024-25 flu season, and about double the number of weekly cases Maine reported three weeks earlier. Flu season runs from October to May, and while the peak of the season can vary, February is often a month when Maine will experience the most new infections.
For the previous week, ending Feb. 8, the Maine CDC reported 1,916 cases.
Hospitalizations for influenza have also climbed, with 145 last week, and 711 total hospitalizations for the season.
Most of the state is considered to be in the "moderate" to "high" category for influenza cases, with Piscataquis and Washington counties in the "very high" category. About 90% of influenza activity is the influenza A strain, and the remaining 10% is influenza B.
There have not been any recorded human cases of bird flu in Maine and no reported domesticated animal cases in 2025. However, Maine has had some cases of bird flu reported in wild animals, and state officials have warned people with chickens, ducks or other domesticated birds to take precautions.
Federal data lags state data by one week, but according to the most recent U.S. CDC data, Maine and much of the nation is considered to have "very high" levels of flu, with the only exceptions being some states in the Midwest and West, including Utah, Nevada and Arizona.
The flu is circulating at the same time as other respiratory illnesses.
Maine is reporting "high" levels of COVID-19 in wastewater, down from "very high" in late January. RSV and norovirus were also reportedly circulating at high levels in Maine this winter, although there is not a robust data tracking of those viruses.
The best way to prevent influenza is to get a flu shot, and it is not too late to get vaccinated. Many places offer flu shots, including primary care offices, pharmacies and other health care settings. Public health experts say to take other measures to prevent illness and the spread of flu, such as frequent hand washing, staying home when sick and avoiding crowded, indoor gatherings.
Influenza symptoms include fever and chills, cough, sore throat, muscle aches, headache, fatigue and a runny nose.
Copy the Story Link

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. removes all current members of CDC vaccine advisory committee
RFK Jr. removes all current members of CDC vaccine advisory committee

Yahoo

time15 hours ago

  • Yahoo

RFK Jr. removes all current members of CDC vaccine advisory committee

US Health and Human Services Secretary Robert F. Kennedy Jr. on Monday dismissed an expert panel of vaccine advisers that has historically guided the federal government's vaccine recommendations, saying the group is 'plagued with conflicts of interest.' The entirety of the 17-member Advisory Committee for Immunization Practices, which advises the US Centers for Disease Control and Prevention on the vaccine schedule and required coverage of immunizations, will be retired and replaced with new members, Kennedy announced in a Wall Street Journal op-ed. The HHS secretary has authority to appoint and dismiss ACIP members, who typically serve four-year cycles. But removing the entire panel prematurely is unprecedented. Kennedy said that a number of the panel's members — traditionally pediatricians, epidemiologists, immunologists and other physicians — were 'last-minute appointees' of the Biden administration. 'Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028,' he wrote. ACIP members are not political appointees. However Kennedy, a longtime critic of federal vaccine policy and vaccine safety, argued that the current group is rife with conflicts of interest and has not been transparent in its vaccine recommendations. ACIP recently considered narrowing the recommendations for Covid-19 vaccinations among children. Kennedy had previously pledged to Sen. Bill Cassidy, a Republican from Louisiana and chairman of the Health, Education, Labor and Pensions Committee, that he would consult with the senator on filling key roles on vaccine advisory boards. A spokesperson for Cassidy did not immediately respond to a request for comment. The committee is scheduled to meet on June 25 to discuss vaccinations against Covid-19, RSV, influenza, HPV and meningococcal disease. HHS said the meeting will still take place, giving the agency roughly two weeks to fill its advisory panel. 'Appointing people this fast means they were not properly vetted, and there is no real time to check conflict of interests issues,' Dorit Reiss, a professor of law at UC Law San Francisco, told CNN. 'This will not restore trust in vaccines, and is not design to do so.'

US FDA approves Merck's RSV antibody for infants
US FDA approves Merck's RSV antibody for infants

Yahoo

time17 hours ago

  • Yahoo

US FDA approves Merck's RSV antibody for infants

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available in the country for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. The approval was based on results from a late-stage trial in which Enflonsia had a comparable safety profile to Swedish Orphan Biovitrum's Synagis, a monthly injection. Merck said that Enflonsia is the first and only RSV preventive option administered to infants using the same dose regardless of weight, and it told Reuters the drug will be priced at $556 per dose. Jefferies analyst Akash Tewari said last year that this is beneficial since physicians have to forecast an infant's potential weight during RSV season with Beyfortus, which makes dose ordering and inventory more complex. In the U.S., an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV each year, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store